07Aug
Investors Pay Close Attention to Shire and Do Not Like What They See
Posted by admin as Business
It was a bad day to be a follower of Shire. Nervousness in the US over possible side effects of its treatments for attention deficit hyperactivity disorder has been growing. Regulators are worried the drugs may cause cardiovascular problems, a worry for the company, which derives as much as a third of the sales from the products.
Sentiment towards the rug developer was hardly helped by Bernstein Research, which told clients that Shire shares were no longer worth buying.
- No Comments
- Tags: Shire